David W. Boyer sold $130k of NBIX
Chief Corp. Affairs Officer at NEUROCRINE BIOSCIENCES INC. 826 shares at an average of $157.45, traded Sep 14, 2026, filed Sep 15, 2026.
Score components
- +15RoleOfficer
- +11Trade size$130k at market
- 0Share of holdings soldSold 8.7% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001909817-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | AGrant or award Common Stock10b5-1 | +3,587 | $0.00 | $0 | 11,484 | 27 d ago |
| Sep 11, 2026 | FTax withholding Common Stock10b5-1 | -1,936 | $156.22 | $302k | 9,548 | 27 d ago |
| Sep 14, 2026 | SOpen-market sale Common Stock10b5-1 | -826 | $157.45 | $130k | 8,722 | 27 d ago |
Related signals
Other insiders at NEUROCRINE BIOSCIENCES INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | NEUROCRINE BIOSCIENCES INC | Matt Abernethy Chief Financial Officer | $363k 2,311 shares | -5% | |
| 10Weak | NEUROCRINE BIOSCIENCES INC | Eric Benevich Chief Commercial Officer | $333k 2,154 shares | -3% | |
| 9Weak | NEUROCRINE BIOSCIENCES INC | Eric Benevich Chief Commercial Officer | $906k 5,970 shares | -12% | |
| 10Weak | NEUROCRINE BIOSCIENCES INC | Kevin Charles Gorman director | $13M 106,322 shares | -17% | |
| 0Weak | NEUROCRINE BIOSCIENCES INC | Ingrid Delaet Chief Regulatory Officer | $62k 457 shares | -9% | |
| 33Weak | NEUROCRINE BIOSCIENCES INC | Jude Onyia Chief Scientific Officer | $7.8M 59,819 shares | -77% | |
| 33Weak | NEUROCRINE BIOSCIENCES INC | Jude Onyia Chief Scientific Officer | $2.6M 20,362 shares | -53% | |
| 20Weak | NEUROCRINE BIOSCIENCES INC | Kevin Charles Gorman director | $1.2M 9,613 shares | -2% | |
| 15Weak | NEUROCRINE BIOSCIENCES INC | William H Rastetter director | $3.3M 30,000 shares | -44% | |
| 16Weak | NEUROCRINE BIOSCIENCES INC | Matt Abernethy Chief Financial Officer | $299k 2,558 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.